Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: Results of a randomized placebo-controlled trial

Stroke

Volumn 43, Issue 6, 2012, Pages 1572-1577

  Hankey, Graeme J ^a   Eikelboom, John W ^b   Yi, Qilong ^c   Lees, Kennedy R ^d   Chen, Christopher ^e   Xavier, Denis ^f   Navarro, Jose C ^g   Ranawaka, Udaya K ^h   Uddin, Wasim ⁱ   Ricci, Stefano ^j   Gommans, John ^k   Schmidt, Reinhold ^l  

^a ROYAL PERTH HOSPITAL   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^g Jose R Reyes Memorial Medical Center   (Philippines)

^h UNIVERSITY OF KELANIYA   (Sri Lanka)

ⁱ POF Hospital   (Pakistan)

^j ASL 1 dell'Umbria   (Italy)

^k HAWKE S BAY HOSPITAL   (New Zealand)

^l MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

prevention; randomized controlled trials

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYANOCOBALAMIN; FOLIC ACID; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; TABLET; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UROGENITAL TRACT CANCER;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; NEOPLASMS; STROKE; VITAMIN B COMPLEX;

EID: 84861610822     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.641613     Document Type: Article

References (21)

1. Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr. 2008;87:517-533.
2. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2007;99:64-76.
3. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132(suppl):2350S-2355S.
4. Sanjoaquin MA, Allen NA, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer. 2005;113:825-838.
5. Li D, Ahmed M, Li Y, Jiao L, Chou T-H, Wolff RA, et al. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1470-1476.
6. Ulrich CM, Neuhouser M, Liu AY, Boynton A, Gregory JFR III, Shane B, et al. Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2008;17:1822-1831.
7. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16: 1325-1329.
8. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 2004;80:1123-1128.
9. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr. 2006;136: 189-194.
10. Wright AJ, Dainty JR, Finglas PM. Folic acid metabolism in human subjects revisited: potential implications for proposed mandatory folic acid fortification in the UK. Br J Nutr. 2007;98:667-675.
11. Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res. 2007;51:267-292.
12. Ulrich CM, Potter JD. Folate and cancer: timing is everything. JAMA. 2007;297:2408-2409.
13. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297: 2351-2359.
14. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134:29-38.
15. Wu K, Plarz EA, Willett WC, Fuchs CS, Selhub J, Rosner BA, et al. A randomized trial of folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr. 2009;90:1623-1631.
16. Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA. 2009;302:2119-2126.
17. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. for the B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010;170:1622-1631.
18. Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Wong L, et al. VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke. 2007;2:144-150.
19. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebocontrolled trial. Lancet Neurol. 2010;9:855-865.
20. Kim YI. Folate and cancer prevention: a new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev. 1999; 57:314-321.
21. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685.